Personalized breast cancer therapy screening
Company 2015
SpheroTec GmbH, Munich, Germany
SpheroTest uses tumor tissue from each individual patient to produce personalised 3D tumor spheroids that are subjected to different cancer medications. Breast cancer patients who took the drug identified as effective with SpheroTest as planned had a tumor freedom rate of over 50%, twice as high as that of patients whose therapy was selected only on the basis of statistical experience without SpheroTest. SpheroTest was able to reliably determine the effective drug for 94% of the patients. Studies on other types of cancer are still ongoing or are in the evaluation.
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy - the SpheroNEO study.
Barbara Mayer
Added on: 05-22-2020
[1] https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1491-7[2] https://www.spherotec.com/
